Uveal melanoma (UM) is a rare cancer that affects the choroid and, less frequently, the ciliary body or the iris (for recent reviews see [1-3]). Despite a profound knowledge of the oncogenic mechanisms behind UM tumorigenesis and despite an accurate cytogenetic and molecular prognosis, only limited advances have been made in UM therapy.

A man in his 90s presented to clinic with a conjunctival lesion on the right eye noticed two months prior. The patient denied pain but endorsed worsening blurry vision. The patient’s past medical history was significant for skin cancer on the right ear removed 3 years ago, and a history of ocular surface lesion removal on one eye approximately 20 years ago that was negative for any neoplasia. Slit lamp photograph revealed a gelatinous and opalescent lesion suspicious for ocular surface squamous neoplasia (OSSN) and the high-resolution optical coherence tomography (HROCT) cut (arrow)

Intratumor heterogeneity has attracted more and more attention in recent years. Heterogeneity is the driving force of tumor clone evolution. Chromosomal instability, somatic mutation, epigenetic modification and extrachromosomal DNA (ecDNA) contribute to tumor heterogeneity. The degree of such heterogeneity is extremely high.

Over the years, several ablation techniques, such as radiofrequency ablation (RFA), microwave ablation, and cryoablation, have been developed and implemented in the treatment of different cancers. Of these ablation technologies, RFA is the most widely used. RFA is a form of thermal ablation that relies on radio waves to produce an electrical current at the tip of an inserted electrode, thus allowing for heat production at the site of the tumor.

Radiation therapy (RT) is one of the pillars of locally advanced head and neck cancer (HNSCC) treatment in combination with cisplatin or epidermal growth factor receptor inhibitors. Despite a very high local tumor control rate, approximately 50% of patients with locally advanced disease will develop a recurrence.